Antibodies to alpha-synuclein

Details Antibodies to alpha-synuclein Antibodies to alpha-synuclein

2011-03-22

2011-03-22

Kolker, Daniel E (Department: 1649)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C530S387300, C530S388100, C530S809000, C435S070210

Reexamination Certificate

active

07910333

ABSTRACT:
The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.

REFERENCES:
patent: 4883666 (1989-11-01), Sabel et al.
patent: 5576184 (1996-11-01), Better et al.
patent: 5589154 (1996-12-01), Anderson
patent: 5753624 (1998-05-01), McMichael
patent: 5780587 (1998-07-01), Potter
patent: 5851996 (1998-12-01), Kline
patent: 5958883 (1999-09-01), Snow
patent: 6504080 (2003-01-01), Van Der Putten
patent: 6710226 (2004-03-01), Schenk
patent: 6743427 (2004-06-01), Schenk
patent: 6761888 (2004-07-01), Schenk
patent: 6780971 (2004-08-01), Wolozin et al.
patent: 6787138 (2004-09-01), Schenk
patent: 6787139 (2004-09-01), Schenk
patent: 6787140 (2004-09-01), Schenk
patent: 6787143 (2004-09-01), Schenk
patent: 6787144 (2004-09-01), Schenk
patent: 6787523 (2004-09-01), Schenk
patent: 6858704 (2005-02-01), Kim
patent: 6866849 (2005-03-01), Schenk
patent: 6866850 (2005-03-01), Schenk
patent: 6890535 (2005-05-01), Schenk
patent: 6923964 (2005-08-01), Schenk
patent: 6946135 (2005-09-01), Schenk et al.
patent: 6972127 (2005-12-01), Schenk
patent: 7014855 (2006-03-01), Schenk
patent: 7060464 (2006-06-01), Kim
patent: 7138255 (2006-11-01), Vodyanoy et al.
patent: 7306945 (2007-12-01), Chilcote et al.
patent: 7358331 (2008-04-01), Chilcote et al.
patent: 7479482 (2009-01-01), Frangione et al.
patent: 2002/0094335 (2002-07-01), Chalifour et al.
patent: 2002/0151464 (2002-10-01), Wolozin et al.
patent: 2002/0160394 (2002-10-01), Wu
patent: 2002/0187157 (2002-12-01), Jensen et al.
patent: 2002/0197258 (2002-12-01), Ghanbari et al.
patent: 2003/0086938 (2003-05-01), Jensen et al.
patent: 2003/0165496 (2003-09-01), Basi et al.
patent: 2003/0166558 (2003-09-01), Frangione et al.
patent: 2003/0185827 (2003-10-01), Rodriguez et al.
patent: 2004/0136993 (2004-07-01), Schenk et al.
patent: 2004/0137523 (2004-07-01), Vodyanoy et al.
patent: 2004/0146521 (2004-07-01), Schenk et al.
patent: 2004/0197831 (2004-10-01), Weksler et al.
patent: 2005/0037013 (2005-02-01), Schenk et al.
patent: 2005/0123544 (2005-06-01), Schenk et al.
patent: 2005/0176078 (2005-08-01), Allsop et al.
patent: 2005/0196818 (2005-09-01), Chilcote et al.
patent: 2005/0198694 (2005-09-01), Chilcote et al.
patent: 2005/0203010 (2005-09-01), Kim
patent: 2005/0255113 (2005-11-01), Huston et al.
patent: 2006/0058233 (2006-03-01), Schenk et al.
patent: 2006/0259986 (2006-11-01), Chilcote et al.
patent: 2008/0014194 (2008-01-01), Schenk et al.
patent: 2008/0175838 (2008-07-01), Schenk et al.
patent: 2009/0208487 (2009-08-01), Schenk et al.
patent: 0 613 007 (1994-08-01), None
patent: 1 633 189 (2006-03-01), None
patent: WO 91/16819 (1991-11-01), None
patent: WO 95/06407 (1995-03-01), None
patent: WO 99/06545 (1999-02-01), None
patent: WO 99/06545 (1999-02-01), None
patent: WO 99/27944 (1999-06-01), None
patent: WO 99/40191 (1999-08-01), None
patent: WO 99/50300 (1999-10-01), None
patent: WO 99/60024 (1999-11-01), None
patent: WO 00/18917 (2000-04-01), None
patent: WO 00/18917 (2000-04-01), None
patent: WO 00/72876 (2000-12-01), None
patent: WO 00/72876 (2000-12-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO 01/06989 (2001-02-01), None
patent: WO 01/06989 (2001-02-01), None
patent: WO 01/53457 (2001-07-01), None
patent: WO 01/53457 (2001-07-01), None
patent: WO 01/60794 (2001-08-01), None
patent: WO 01/60794 (2001-08-01), None
patent: WO 02/03911 (2002-01-01), None
patent: WO 03/000714 (2003-01-01), None
patent: WO 03/000714 (2003-01-01), None
patent: WO 03/045128 (2003-06-01), None
patent: WO 03/045128 (2003-06-01), None
patent: WO 2004/009625 (2004-01-01), None
patent: WO 2004/009625 (2004-01-01), None
patent: WO 2004/041067 (2004-05-01), None
patent: WO 2004/041067 (2004-05-01), None
patent: WO 2005/013889 (2005-02-01), None
patent: WO 2005/047860 (2005-05-01), None
patent: WO 2005/047860 (2005-05-01), None
patent: WO 2006/020581 (2006-02-01), None
patent: WO 2006/020581 (2006-02-01), None
patent: WO 2006/045037 (2006-04-01), None
patent: WO 2006/045037 (2006-04-01), None
patent: WO 2007/011907 (2007-01-01), None
patent: WO 2007/012061 (2007-01-01), None
patent: WO 2007/021255 (2007-02-01), None
patent: WO 2008/103472 (2008-08-01), None
U.S. Appl. No. 12/528,439, filed Aug. 24, 2009, Schenk et al.
U.S. Appl. No. 11/894,772, filed Aug. 20, 2007, Schenk et al.
U.S. Appl. No. 11/894,744, filed Aug. 20, 2007, Schenk et al.
U.S. Appl. No. 11/894,605, filed Aug. 20, 2007, Schenk et al.
U.S. Appl. No. 11/841,996, filed Aug. 20, 2007, Schenk et al.
U.S. Appl. No. 11/660,015, filed Feb. 9, 2007, Schenk et al.
U.S. Appl. No. 10/850,570, filed May 19, 2004, Chilcote et al.
U.S. Appl. No. 60/518,140, filed Nov. 8, 2003, Chilcote et al.
U.S. Appl. No. 60/471,929, filed May 19, 2003, Chilcote et al.
U.S. Appl. No. 60/423,012, filed Nov. 1, 2002, Schenk et al.
Abbas et al.,Cellular and Molecular Immunology, 522-523 (Elsevier Saunders) (5th Ed. Updated Ed., 2005).
Anderson et al., “Phosphorylation of SER-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease,” The Journal of Biological Chemistry, 281:29739-29752 (2006).
Alves da Costa, “Recent Advances on α-Synuclein Cell Biology : Functions and Dysfunctions,” Current Molecular Medicines, 3:17-24 (2003).
Bales et al., “Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody,”J. Clin. Invest., 116(3):825-832 (2006).
Bard et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,”Nature Medicine, 6(8):916-919 (2000).
Bennett et al., “Degradation of α-Synuclein by Proteasome,”J. Biol. Chem., 274(48):33855-33858 (1999).
Bodles et al., “Toxicity of non-Aβ component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of β-sheet structure and fibrils,”Eur. J. Biochem., 267:2186-2194 (2000).
Brooks et al., “Synuclein proteins and Alzheimer's disease,” Trends Neurosci., 17(10):404-405 (1994).
Cao et al., “Development of an Alpha Synuclein Recombinant Protein as a Potential Candidate Against Parkinson's Disease,” Program No. 594.3, Abstract Viewer/Itinerary Planner, Washington D.C.: Society for Neuroscience (2002).
Casadesus et al., “The Estrogen Myth; Potential Use of Gonadotropin-releasing hormone Agonists for Treatment of Alzheimer's Disease,” Drugs R&D, 7(3):187-193 (2006).
Chang et al., “Adjuvant activity of incomplete Freund's adjuvant,”Advanced Drug Delivery Reviews, 32:173-186 1998).
Chapman, “Model behaviour,”Nature, 408:915-916 (2000).
Chen et al., “Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgneic mice,”Progress in Brain Research, 117:327-337 (1998).
Chilcote et al., “Comparison of alpha-synuclein species in Lewy bodies and the soluble fraction of diffuse Lewy body disease brain,” Database Biosis [Online] Biosciences Information Service, Philadelphia, PA, US (2003) Abstract only.
Clayton et al., “Synucleins in Synaptic Plasticity and Neurodegenerative Disorders,”J. Neurosci. Res., 58:120-129 (1999).
Clayton et al, “The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration, and disease,”Trends Neurosci., 21(6):249-254 (1998).
Cleland et al., “Isomerization and Formulation Stability of the Vaccine Adjuvant QS-21,”J.of Pharm Sci., 85(1): 22-28 (1996).
Conway et al., “Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy,” PNAS, 97(2):571-576 (2000).
Crowther et al., “Synthetic filaments as

Affiliated with

Also associated with

Rating

Antibodies to alpha-synuclein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to alpha-synuclein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to alpha-synuclein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2708567